

RECEIVED

1632

JAN 08 2003

#141B

RD

1-13-03



TECH CENTER 1600/2900

INEX.P-006

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Semple et al

Serial No.: 09/649,527

Examiner: D. Nguyen

Filed: August 26, 2000

Art Unit: 1632

Title: Compositions for Stimulating Cytokine Secretion and Inducing an Immune Response

RESPONSE TO NOTICE OF NON-RESPONSIVE AMENDMENT

Responding the Notice of non-responsive amendment mailed December 2, 2002 for the above-captioned application, applicants enclose a revised amendment which includes the argument with respect to the 103 rejection which was inadvertently omitted in the previous filing. Entry of the amendment, as enclosed, and further examination of the application are respectfully requested.

No fees are believed to be due with this paper. However, the Commissioner is authorized to charge any fees deemed due to Deposit Account No. 15-0610.

Respectfully submitted,

*Marina T. Larson*

Marina T. Larson Ph.D.  
PTO Reg. No. 32,038  
Attorney for Applicant  
(970) 468-6600

I hereby certify that this paper and any attachments named herein are being deposited with the US Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on January 2, 2003.

*Marina T. Larson*

Marina T. Larson, PTO Reg. No. 32,038

January 2, 2003

Date of Signature

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

INEX.P-006

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Semple et al

Serial No.: 09/649,527

Examiner: D. Nguyen

Filed: August 26, 2000

Art Unit: 1632

Title: Compositions for Stimulating Cytokine Secretion and Inducing an Immune Response

AMENDMENT

Responsive to the Official Action mailed March 28, 2002 for the above-captioned application, please make the following amendments:

In the claims:

Please cancel claims 4 and 15 without prejudice.

Please amend claims 6 and 17 to read as follows:

6. The composition according to claim 1, wherein the cationic lipid is  
B1 selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol and DDAB.

17. The composition according to claim 11, wherein the cationic lipid is  
B2 selected from among DODAP, DODMA, DMDMA, DOTAP, DC-Chol and DDAB.

REMARKS

This is in response to the Official Action mailed March 28, 2002 for the above-captioned application. Reconsideration of the application in view of the remarks herein is respectfully requested.